Mao Inhibitors + Ripretinib Interaction
Moderateinteraction on record
Description
Coadministration increases ripretinib and active metabolite (DP-5439) exposure, which may increase the risk of adverse reactions. Monitor patients more frequently.
Mechanism
CYP3A inhibition
Source: NLP:ripretinib